Is Immunoprecise Antibodies Stock a Good Investment?
Immunoprecise Antibodies Investment Advice | IPA |
- Examine Immunoprecise Antibodies' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Immunoprecise Antibodies' leadership team and their track record. Good management can help Immunoprecise Antibodies navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Immunoprecise Antibodies' business and its evolving consumer preferences.
- Compare Immunoprecise Antibodies' performance and market position to its competitors. Analyze how Immunoprecise Antibodies is positioned in terms of product offerings, innovation, and market share.
- Check if Immunoprecise Antibodies pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Immunoprecise Antibodies' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Immunoprecise Antibodies stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Immunoprecise Antibodies is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Immunoprecise Antibodies Stock
Researching Immunoprecise Antibodies' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book (P/B) ratio of 0.88. Some equities with similar Price to Book (P/B) outperform the market in the long run. Immunoprecise Antibodies recorded a loss per share of 0.75. The entity last dividend was issued on the 23rd of November 2020. The firm had 1:5 split on the 23rd of November 2020.
To determine if Immunoprecise Antibodies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Immunoprecise Antibodies' research are outlined below:
| Immunoprecise Antibodies had very high historical volatility over the last 90 days | |
| Immunoprecise Antibodies has some characteristics of a very speculative penny stock | |
| Immunoprecise Antibodies has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 24.52 M. Reported Net Loss for the year was (27.18 M) with profit before taxes, overhead, and interest of 12.1 M. | |
| Immunoprecise Antibodies has about 19.24 M in cash with (4.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Immunoprecise Antibodies has a frail financial position based on the latest SEC disclosures |
Immunoprecise Antibodies uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Immunoprecise Antibodies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immunoprecise Antibodies' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 8th of July 2024 Next Financial Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View | |
| 8th of July 2024 Next Fiscal Year End | View | |
| 31st of October 2023 Last Quarter Report | View | |
| 30th of April 2023 Last Financial Announcement | View |
Immunoprecise Antibodies' market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 20.14 M.Immunoprecise Antibodies' profitablity analysis
The company has Net Profit Margin of (1.16) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.46) %, which entails that for every $100 of revenue, it lost $0.46.Determining Immunoprecise Antibodies' profitability involves analyzing its financial statements and using various financial metrics to determine if Immunoprecise Antibodies is a good buy. For example, gross profit margin measures Immunoprecise Antibodies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Immunoprecise Antibodies' profitability and make more informed investment decisions.
Please note, the presentation of Immunoprecise Antibodies' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Immunoprecise Antibodies' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Immunoprecise Antibodies' management manipulating its earnings.
Basic technical analysis of Immunoprecise Stock
As of the 26th of March, Immunoprecise Antibodies retains the Market Risk Adjusted Performance of 0.7347, risk adjusted performance of 0.0426, and Downside Deviation of 5.89. Immunoprecise Antibodies technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Immunoprecise Antibodies' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunoprecise Antibodies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunoprecise Antibodies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunoprecise Antibodies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aisling Capital Ii Lp over a week ago Acquisition by Aisling Capital Ii Lp of 10412 shares of Immunoprecise Antibodies subject to Rule 16b-3 |
Immunoprecise Antibodies' Outstanding Corporate Bonds
Immunoprecise Antibodies issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immunoprecise Antibodies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immunoprecise bonds can be classified according to their maturity, which is the date when Immunoprecise Antibodies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Immunoprecise Antibodies' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Immunoprecise Antibodies' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0426 | |||
| Market Risk Adjusted Performance | 0.7347 | |||
| Mean Deviation | 5.66 | |||
| Semi Deviation | 5.3 | |||
| Downside Deviation | 5.89 | |||
| Coefficient Of Variation | 2505.8 | |||
| Standard Deviation | 7.56 | |||
| Variance | 57.1 | |||
| Information Ratio | 0.0389 | |||
| Jensen Alpha | 0.2925 | |||
| Total Risk Alpha | 0.3135 | |||
| Sortino Ratio | 0.0499 | |||
| Treynor Ratio | 0.7247 | |||
| Maximum Drawdown | 42.15 | |||
| Value At Risk | (9.76) | |||
| Potential Upside | 13.16 | |||
| Downside Variance | 34.75 | |||
| Semi Variance | 28.04 | |||
| Expected Short fall | (8.15) | |||
| Skewness | 1.31 | |||
| Kurtosis | 3.14 |
| Risk Adjusted Performance | 0.0426 | |||
| Market Risk Adjusted Performance | 0.7347 | |||
| Mean Deviation | 5.66 | |||
| Semi Deviation | 5.3 | |||
| Downside Deviation | 5.89 | |||
| Coefficient Of Variation | 2505.8 | |||
| Standard Deviation | 7.56 | |||
| Variance | 57.1 | |||
| Information Ratio | 0.0389 | |||
| Jensen Alpha | 0.2925 | |||
| Total Risk Alpha | 0.3135 | |||
| Sortino Ratio | 0.0499 | |||
| Treynor Ratio | 0.7247 | |||
| Maximum Drawdown | 42.15 | |||
| Value At Risk | (9.76) | |||
| Potential Upside | 13.16 | |||
| Downside Variance | 34.75 | |||
| Semi Variance | 28.04 | |||
| Expected Short fall | (8.15) | |||
| Skewness | 1.31 | |||
| Kurtosis | 3.14 |
Consider Immunoprecise Antibodies' intraday indicators
Immunoprecise Antibodies intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Immunoprecise Antibodies stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Immunoprecise Antibodies time-series forecasting models is one of many Immunoprecise Antibodies' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunoprecise Antibodies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Immunoprecise Stock media impact
Far too much social signal, news, headlines, and media speculation about Immunoprecise Antibodies that are available to investors today. That information is available publicly through Immunoprecise media outlets and privately through word of mouth or via Immunoprecise internal channels. However, regardless of the origin, that massive amount of Immunoprecise data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Immunoprecise Antibodies news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immunoprecise Antibodies relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immunoprecise Antibodies' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immunoprecise Antibodies alpha.
Immunoprecise Antibodies Corporate Management
| Kari Graber | Vice Services | Profile | |
| Brad McConn | Chief Officer | Profile | |
| Barry Duplantis | VP Relations | Profile | |
| Ilse Roodink | Chief Officer | Profile | |
| David Orton | Chief Officer | Profile | |
| Joseph Scheffler | Interim Officer | Profile | |
| Roland Romijn | Head IPA | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Immunoprecise Antibodies' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.